Peripheral sub-inflammation is associated with antidepressant ă consumption in schizophrenia. Results from the multi-center FACE-SZ data ă set

G. Fond (), O. Godin (), L. Brunel, Bruno Aouizerate (), F. Berna (), E. Bulzacka, D. Capdevielle (), I. Chereau, J. M. Dorey, C. Dubertret, J. Dubreucq, C. Faget, F. Gabayet, Y. Le Strat, J. A. Micoulaud-Franchi, D. Misdrahi (), R. Rey, R. Richieri, C. Passerieux (), A. Schandrin (), F. Schuerhoff, A. M. Tronche, M. Urbach, P. Vidalhet, P. M. Llorca (), M. Leboyer () and Face-Sz Fondamental Acad Ctr
Additional contact information
L. Brunel: UMS - United Monolithic Semiconductors
E. Bulzacka: IMRB - Institut Mondor de Recherche Biomédicale - INSERM - Institut National de la Santé et de la Recherche Médicale - UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12, Service de psychiatrie - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - Hôpital Albert Chenevier, Fondation FondaMental [Créteil]
D. Capdevielle: UM1 - Université Montpellier 1, INSERM U-888 - INSERM - Institut National de la Santé et de la Recherche Médicale
Y. Le Strat: Département des maladies infectieuses - INVS - Institut de Veille Sanitaire
J. A. Micoulaud-Franchi: Hôpitaux Sud - Département Universitaire de Psychiatrie - [Hôpital Sainte Marguerite - APHM] - AMU - Aix Marseille Université - APHM - Assistance Publique - Hôpitaux de Marseille - Hôpitaux Sud - Hôpital Sainte-Marguerite [CHU - APHM], LNC - Laboratoire de Neurosciences Cognitives [Marseille] - AMU - Aix Marseille Université - CNRS - Centre National de la Recherche Scientifique
R. Rey: ONERA - The French Aerospace Lab [Toulouse] - ONERA
R. Richieri: Departement de Psychiatrie - LA CONCEPTION - Hôpital de la Conception [CHU - APHM], SPMC - Santé Publique et maladies Chroniques : Qualité de vie Concepts, Usages et Limites, Déterminants - AMU - Aix Marseille Université - APHM - Assistance Publique - Hôpitaux de Marseille

Post-Print from HAL

Abstract: Objectives: The relation between C-Reactive Protein (CRP), depression ă and antidepressant consumption has been well explored in major ă depressive disorders but not in schizophrenia, which has a high rate of ă depression comorbidity. The objectives of this study were: (i) to ă determine the prevalence of abnormal CRP levels, depression and ă antidepressant consumption in a multicenter community-dwelling sample of ă subjects with schizophrenia (ii) to determine the association between ă abnormal CRP levels, depression and antidepressant consumption in ă schizophrenia. ă Method: 219 stable patients with schizophrenia (mean age=31.6 years, ă 75.3% male gender) were systematically included in the multicentre ă network of FondaMental Expert Center for schizophrenia (FACESZ) and ă assessed with a dedicated electronic medical record including the ă Structured Clinical Interview for DSM-IV Axis I Disorders and Calgary ă Depression Scale for depression. High sensitivity CRP (hs-CRP) was ă measured with an assay using nephelometry (Dade Behring). Abnormal CRP ă level was defined by levels > 3 mg/L. Current medication was recorded. ă Results: Overall, 63 subjects (28.8%) were found to have abnormal CRP ă levels, 43 (20.1%) received a diagnosis of comorbid current depression, ă and 51 (31.9%) had ongoing antidepressant treatment. In univariate ă analysis, abnormal CRP levels were found to be significantly associated ă with body mass index (BMI) (p 0.05). ă In a multivariate model, abnormal CRP was associated with antidepressant ă consumption independently of other confounding variables (adjusted Odds ă Ratio =2.8, 95% confidence interval 1.226.62). Metabolic syndrome was ă also independently associated with abnormal CRP (adjusted Odds Ratio = ă 2.6, 95% confidence interval 1.01-6.71). ă Conclusion: Abnormal CRP levels in schizophrenia were found to be ă associated with antidepressant consumption, but not with depression. The ă potential mechanisms were discussed. Antidepressant consumption should ă be systematically recorded in future studies exploring inflammation in ă schizophrenia. Future clinical trials of interventions directed at ă lowering the level of CRP and other inflammatory markers are discussed. ă (c) 2015 Elsevier BY. All rights reserved.

Keywords: Quality (search for similar items in EconPapers)
Date: 2016-02
References: Add references at CitEc
Citations:

Published in Journal of Affective Disorders, 2016, 191, pp.209-215. ⟨10.1016/j.jad.2015.11.017⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01482510

DOI: 10.1016/j.jad.2015.11.017

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().